Home › Research › Biomarkers
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease
Pichet Binette A, Smith R, Salvadó G, Tideman P, Glans I, van Westen D, Groot C, Ossenkoppele R et al.. JAMA neurology, 2025-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included. In BioFINDER-2, 37.7% of the sample had congruent biological and clinical stages (reference group), 51.3% had more advanced clinical impairment compared with their clinical stage (clinical > biological) and 11.0% had the opposite (biological > clinical). These results highlight the importance of measuring non-AD biomarkers in patients with AD with worse cognitive impairment than expected based on their biological stage, which could impact the clinical diagnosis and prognosis.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 838 participants. The results highlight the importance of measuring non-AD biomarkers in patients with worse cognitive impairment than expected from their biological stage, which could affect clinical diagnosis and prognosis, but no treatment, cure, or prevention is reported. Reported effect size: 37.7%; 51.3%; 11.0%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pichet Binette, A., Smith, R., Salvadó, G., Tideman, P., Glans, I., van Westen, D., et al. (2025). Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA neurology. https://doi.org/10.1001/jamaneurol.2025.1100
Vancouver
Pichet Binette A, Smith R, Salvadó G, Tideman P, Glans I, van Westen D, et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA neurology. 2025. doi:10.1001/jamaneurol.2025.1100. PMID: 40388185.
BibTeX
@article{pichetbinette2025-40388185,
author = {Pichet Binette, A. and Smith, R. and Salvadó, G. and Tideman, P. and Glans, I. and van Westen, D. and Groot, C. and Ossenkoppele, R. and others},
title = {{Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease}},
journal = {JAMA neurology},
year = {2025},
doi = {10.1001/jamaneurol.2025.1100},
pmid = {40388185},
url = {https://doi.org/10.1001/jamaneurol.2025.1100}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results There were 838 BioFINDER-2 participants (mean age, 73.9 [SD, 7.3] years; 431 women [51%]; 407 men [49%]) and 380 ADNI participants (average age, 72.9 [SD, 7.0] years; 194 women [51%]; 186 mean [49%]) included.
- In BioFINDER-2, 37.7% of the sample had congruent biological and clinical stages (reference group), 51.3% had more advanced clinical impairment compared with their clinical stage (clinical > biological) and 11.0% had the opposite (biological > clinical).
- These results highlight the importance of measuring non-AD biomarkers in patients with AD with worse cognitive impairment than expected based on their biological stage, which could impact the clinical diagnosis and prognosis.
Why it matters
In this evaluation of revised criteria for biological and clinical staging of Alzheimer disease, only 37.7% of the BioFINDER-2 sample had congruent biological and clinical stages, while 51.3% had more advanced clinical impairment than their clinical stage and 11.0% had the opposite. The results highlight the importance of measuring non-AD biomarkers in patients with worse cognitive impairment than expected from their biological stage, which could affect clinical diagnosis and prognosis, but no treatment, cure, or prevention is reported.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants838
- Effect size37.7%; 51.3%; 11.0%
- Evidence strengthModerate
How this study scored 68/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 838 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 63 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 39.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 3 / 4 | Cited 63 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ian B. Malone: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 19 institution(s) in 8 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40388185) |
| Free to read | 2 / 2 | Free to read |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2025.1100
- PubMed: 40388185
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also in Biomarkers
141 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.